Addex Therapeutics (ADXN) CEO files Form 3 showing large share and option stake

Rhea-AI Filing Summary

Addex Therapeutics Ltd. Chief Executive Officer Timothy Mark Dyer filed an initial insider ownership report. He reports direct ownership of 16,848,979 shares of common stock listed on SIX Swiss Exchange. This filing does not show new purchases or sales; it establishes his existing position.

Dyer also holds stock options giving the right to buy 3,369,796 shares of common stock at an exercise price of $0.064 per share. These options vest in equal monthly installments over four years starting on the exercisable date of January 8, 2024 and expire on January 7, 2034. The exercise price is shown in U.S. dollars based on a stated CHF-to-USD exchange rate as of March 12, 2026.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dyer Timothy Mark

(Last) (First) (Middle)

CHEMIN DES MINES 9

(Street)

GENEVA CH-1202

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Addex Therapeutics Ltd. [ ADXN ]

3a. Foreign Trading Symbol
[ADXN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common stock	16,848,979(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock-Option (Right to Buy)	01/08/2024(2)	01/07/2034	Common stock	3,369,796	$0.064(3)	D

Explanation of Responses:

1. Represents 16,848,979 shares of Common Stock listed on SIX Swiss Exchange.

2. The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants the right to purchase one ADXN share listed on SIX Swiss Exchange.

3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.2769 per CHF 1.00 as of March 12, 2026.

	/s/ Timothy Mark Dyer	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Addex Therapeutics (ADXN) Form 3 filing report for Timothy Mark Dyer?

The Form 3 reports Timothy Mark Dyer’s initial insider holdings in Addex Therapeutics. He directly holds 16,848,979 common shares listed on SIX Swiss Exchange, plus stock options over 3,369,796 shares, establishing his baseline ownership as a director, officer, and significant holder.

How many Addex Therapeutics (ADXN) common shares does Timothy Mark Dyer hold?

Timothy Mark Dyer reports beneficial ownership of 16,848,979 common shares of Addex Therapeutics. These shares are listed on SIX Swiss Exchange and are held directly, according to the Form 3 insider ownership statement, without indicating any recent purchase or sale transaction.

What stock options in Addex Therapeutics (ADXN) does Timothy Mark Dyer report?

Dyer reports stock options covering 3,369,796 Addex Therapeutics common shares at a reported exercise price of $0.064 per share. The options vest in equal monthly installments over four years from January 8, 2024 and expire on January 7, 2034, indicating a long-term incentive position.

How do Timothy Mark Dyer’s Addex (ADXN) stock options vest over time?

The stock options vest in equal monthly installments over a four-year period beginning on the exercisable date of January 8, 2024. Each option grants the right to purchase one ADXN share listed on SIX Swiss Exchange, creating a gradual, time-based equity incentive for the CEO.

How was the Addex Therapeutics (ADXN) option exercise price determined in the Form 3?

The exercise price of $0.064 per share for the reported stock options reflects a conversion from Swiss francs to U.S. dollars. It is based on an exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026, as specifically described in the footnotes.

Does the Addex Therapeutics (ADXN) Form 3 show any insider buying or selling by Timothy Mark Dyer?

The Form 3 does not show any new insider purchases or sales by Timothy Mark Dyer. Instead, it lists his existing direct holdings of common stock and his stock option position, serving as an initial statement of beneficial ownership for regulatory disclosure.